Omega-3 fatty acids are among the most widely taken supplements by women in midlife. The marketing is expansive: joint health, heart health, mood, memory, hot flash relief. Some of these claims have solid evidence. Others do not. Understanding the difference matters when you are deciding whether a supplement is earning its place.
What Omega-3 Fatty Acids Are
The term omega-3 covers a family of polyunsaturated fatty acids. The two most relevant for health outcomes are EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), found primarily in oily fish. A third, ALA (alpha-linolenic acid), comes from plant sources like flaxseed and walnuts, but the body converts only a small fraction of ALA into the more active EPA and DHA.
When research refers to omega-3 benefits, it is almost always referring to EPA and DHA, from dietary sources or concentrated fish oil supplements.
What the Research Does Not Support: Hot Flashes
A 2023 systematic review of randomised controlled trials of omega-3 supplementation in postmenopausal women assessed effects on vasomotor symptoms, sleep quality, and depression.[1] The conclusion on hot flashes was clear: the combined analysis did not provide substantial evidence to support efficacy for improving vasomotor symptoms.
This is consistent with the MsFLASH trial, one of the larger rigorous trials in this space. It tested omega-3 supplementation in healthy perimenopausal and postmenopausal women and found no improvement in vasomotor symptom frequency, bother, sleep, or mood compared to placebo.[2]
If you are taking omega-3 for hot flashes, the evidence does not support that use.
What the Research Does Support: Mood and Depression
The evidence for omega-3 and mood is more robust, and in the context of menopause this is clinically relevant.
EPA and DHA are structural components of cell membranes in the brain, including in regions involved in mood regulation. They support mood through several mechanisms: reducing neuroinflammation, supporting neurotransmitter function (particularly serotonin and dopamine), and promoting neuroplasticity.[3]
Meta-analyses of omega-3 for depression in general adult populations show clinically meaningful effects, particularly at higher EPA doses. The evidence is strongest when EPA predominates over DHA, typically in formulations with an EPA:DHA ratio of at least 2:1.[3]
In the specific context of menopause, one cross-sectional study of postmenopausal women found an inverse association between dietary omega-3 intake and depression scores, independent of other dietary factors.[4] An earlier open trial in perimenopausal and postmenopausal women with depression found omega-3 supplementation produced clinically significant reductions in depressive symptoms over eight weeks.[5]
The picture: omega-3 has credible biological mechanisms and some trial data supporting mood benefits in menopausal women, particularly when depression or mood instability is the target, not vasomotor symptoms.
Inflammation: The Broader Relevance
Menopause is associated with increased low-grade systemic inflammation. Estrogen has anti-inflammatory properties, and its decline elevates markers such as IL-6, TNF-alpha, and CRP. This inflammatory shift contributes to joint pain, muscle loss, cognitive changes, and cardiovascular risk.
EPA is substrate for anti-inflammatory eicosanoids and reduces the production of pro-inflammatory cytokines including IL-6 and TNF-alpha.[6] This is relevant across multiple symptom domains, not just mood. The research on omega-3 for joint pain has enough support in osteoarthritis and rheumatoid arthritis to be included in some clinical guidelines.[6]
This anti-inflammatory effect also underlies the association between omega-3 intake and lower cardiovascular risk. During the menopausal transition, when cardiovascular risk begins to rise, maintaining adequate omega-3 intake is supported by the broader cardiovascular literature independently of menopause-specific studies.
Dietary Sources Versus Supplements
Dietary sources of EPA and DHA are preferable to supplements where achievable. Oily fish (salmon, mackerel, sardines, anchovies, herring) provide EPA and DHA in a food matrix that includes other nutrients, and food-based omega-3 intake has a stronger evidence base than supplementation across most health outcomes.
Practical target from most dietary guidelines: two portions of oily fish per week, providing approximately 500–700 mg EPA+DHA combined per day.
For women who do not eat fish, algae-based omega-3 supplements provide EPA and DHA directly. Algae are the original source; fish accumulate them through the food chain. These are an evidence-based alternative with a similar nutrient profile to fish oil.
When supplementing, the evidence favours higher EPA relative to DHA for mood-related benefits. Look for combined EPA+DHA of at least 1 gram per day with EPA predominating. The supplement market is poorly regulated and purity varies; third-party tested products (IFOS or USP certification) are a reasonable quality filter.
Evidence Summary
| Claim | Evidence status |
|---|---|
| Reduces hot flash frequency | Not supported by RCT evidence |
| Reduces depressive symptoms | Moderate support, particularly at higher EPA doses |
| Reduces systemic inflammation | Well-supported mechanistically and in RCTs |
| Supports cardiovascular health | Well-supported in broader population literature |
| Reduces joint pain | Some support in arthritis literature |
Omega-3 supplementation or consistent dietary intake is worth considering during the menopausal transition, primarily for its anti-inflammatory, cardiovascular, and mood-related effects. It is not a treatment for vasomotor symptoms. Much of the supplement marketing presents it as such, which overstates the evidence and may lead women to prioritise it over more effective interventions for their primary symptom.
References
[1] Mehdizadeh, A., Ghazanfarpour, M., Heshmat-Ghahdarijani, K., et al. (2023). Effects of omega-3 polyunsaturated fatty acids intake on vasomotor symptoms, sleep quality and depression in postmenopausal women: A systematic review. Post Reproductive Health, 29(4). https://pmc.ncbi.nlm.nih.gov/articles/PMC10574492/
[2] Cohen, L. S., Joffe, H., Guthrie, K. A., et al. (2014). Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Menopause, 21(4), 347-354. https://pmc.ncbi.nlm.nih.gov/articles/PMC4072122/
[3] Liao, Y., Xie, B., Zhang, H., et al. (2019). Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry, 9, 190. See also: Omega-3 polyunsaturated fatty acids in depression. https://pmc.ncbi.nlm.nih.gov/articles/PMC11354246/
[4] Chiu, C. C., Su, K. P., Cheng, T. C., et al. (2021). Association between dietary omega-3 fatty acid intake and depression in postmenopausal women. Nutrients, 13(7). https://pmc.ncbi.nlm.nih.gov/articles/PMC8313386/
[5] Lucas, M., Asselin, G., Merette, C., Poulin, M. J., Dodin, S. (2009). Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial. European Neuropsychopharmacology, 19(12), 897-904. https://pubmed.ncbi.nlm.nih.gov/21037490/
[6] Calder, P. C. (2015). Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochimica et Biophysica Acta, 1851(4), 469-484. https://doi.org/10.1016/j.bbalip.2014.08.010
Vona
Menopause and perimenopause tracking, with clinical reports.
Vona surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.